SPDYE7P

Across TCGA pan-cancer cohorts, SPDYE7P Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPDYE7P data layer compared with 14 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPDYE7P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPDYE7P expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

LUAD, OV, and UCEC are the cancer types where SPDYE7P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	21	view →
OV	OS	Median	III,IV	1.000	0.311	.042	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
COAD	OS	Median	All	0.184	0.799	.008	6	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
SKCM	OS	Median	All	0.594	0.878	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPDYE7P–LUAD (DFS)

Open the LUAD breakdown →